Atmo Biosciences is pleased to announce that the European Patent Office and IP Australia have each granted patents related to key intellectual property for Atmo’s ingestible gas sensor capsule, providing coverage until 2037.  

This follows the recent granting of the equivalent patent in the USA which was announced in September 2022.

The Atmo Gas Capsule is the world’s first ingestible gas-sensing capsule and is being developed for monitoring gastrointestinal health and microbiome function. These granted patents protect the ingestible capsule’s unique gas-sensing functionality and its ability to wirelessly transmit the data it collects. Atmo has an exclusive, worldwide license for the patent from RMIT University—where the technology was initially invented.

Malcolm Hebblewhite, Atmo CEO and Managing Director commented: “These patents further build upon Atmo Biosciences’ strong, foundational intellectual property position in three of its key commercial markets. These patents are important components of Atmo’s IP portfolio which covers the Atmo Gas Capsule System as well as future applications of the technology. Atmo is continuing to build its intellectual property position for this system and has lodged five additional patent applications during this calendar year.”

Due to the difficulty in accessing the human GI tract, the diagnosis and management of functional gastrointestinal disorders (FGIDs) is currently hampered by the challenges of gathering meaningful data directly from the site of the disease. Using its unique ingestible, gas-sensing capsule platform, Atmo is able to provide direct insights into both the microbiome and the functional physiology of the human GI tract. FGIDs affect approximately 40% of the world’s population and over two-thirds of diagnosed patients are believed to have seen a doctor in the last year in relation to their gastrointestinal health.

Professor Calum Drummond, Deputy Vice-Chancellor Research and Innovation at RMIT University, said, “It is extremely gratifying to see patents covering intellectual property that started at RMIT being successfully granted in key markets. We are delighted to be supporting Atmo as it develops this intellectual property into products and applications that are likely to have a significant impact on the lives of patients who suffer from functional gut disorders.”